BAX vs EXEL: fair value comparison
Baxter International Inc. and Exelixis, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EXEL currently sits closer to the top of our discount ranking. EXEL carries the stronger quality grade.
| BAX | EXEL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $23.80 | $56.89 |
| 12-month range | $16.78–$28.10 | $38.06–$56.89 |
| Sector rank | #54 of 113 Healthcare | #53 of 113 Healthcare |
| Quality grade | F | A |
| Leverage | High | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BAX fair value analysis · EXEL fair value analysis